

Figure S1




Figure S1. Effect of 4-hydroxytamoxifen on astrocytes viability. Primary astrocyte cultures were treated with different concentrations of TAM ranging from 0.1 μ M to 100 μ M for 6, 12, 24 and 72 hours. Cell viability was assessed using the MTT assay. The results expressed as the percentage of viable astrocytes following TAM treatment relative to the viability prior to treatment (0 h). Data represent means $\pm$ SE, *** p <0.001, ** p <0.01, * p <0.05, 'ns' is non-significant - compared to mock-treated control, n =3 independent primary cell culture preparations.

Figure S2




Figure S2. Tamoxifen treatment of astrocytes isolated from adult, non-infected mice. Primary astrocytes were treated with TAM or mock solution for 72 hours and analyzed. Upper panels: immunofluorescence microscopy images of Cre^{+/+} (A) and Cre^{-/-} astrocytes (B) co-immunostained for GFAP and Stat3 along with DAPI. Lower panels: quantification of integrated fluorescence intensity for Stat3 and morphometric analyses of cell area, perimeter and process number in Cre^{+/+} (A) and Cre^{-/-} astrocytes (B). Images are representatives of three cultures originating from independent animals per experimental group. For integrated intensity, n=10 random fields with 7–8 cells per field of view from three independent cultures, each prepared from an individual animal, per group. For morphometric analysis, n=90–100 cells from three independent cultures, each prepared from an individual animal, per group. In SuperPlots: colors represent independent experiments; dots represent in individual fields of view or cells; average values for each experiment are shown as large circles; statistical analyses were performed based on the number of independent experiments; black lines mark means. 'ns' non-significant by two-tailed, unpaired t-test.

Figure S3**List of protein included in the array**

Coordinate	Target/Control	Alternate Nomenclature
A1, A2	Reference Spot	—
A23, A24	Reference Spot	—
B1, B2	BLC	CXCL13/BCA-1
B3, B4	C5/C5a	Complement Component 5a
B5, B6	G-CSF	—
B7, B8	GM-CSF	—
B9, B10	I-309	CCL1/TCA-3
B11, B12	Eotaxin	CCL11
B13, B14	ICAM-1	CD54
B15, B16	IFN- γ	—
B17, B18	IL-1 α	IL-1F1
B19, B20	IL-1 β	IL-1F2
B21, B22	IL-1ra	IL-1F3
B23, B24	IL-2	—
C1, C2	IL-3	—
C3, C4	IL-4	—
C5, C6	IL-5	—
C7, C8	IL-6	—
C9, C10	IL-7	—
C11, C12	IL-10	—
C13, C14	IL-13	—
C15, C16	IL-12 p70	—
C17, C18	IL-16	—
C19, C20	IL-17	—
C21, C22	IL-23	—
C23, C24	IL-27	—
D1, D2	IP-10	CXCL10/CRG-2
D3, D4	I-TAC	CXCL11
D5, D6	KC	CXCL1
D7, D8	M-CSF	—
D9, D10	JE	CCL2/MCP-1
D11, D12	MCP-5	CCL12
D13, D14	MIG	CXCL9
D15, D16	MIP-1 α	CCL3
D17, D18	MIP-1 β	CCL4
D19, D20	MIP-2	CXCL2
D21, D22	RANTES	CCL5
D23, D24	SDF-1	CXCL12
E1, E2	TARC	CCL17
E3, E4	TIMP-1	—
E5, E6	TNF- α	—
E7, E8	TREM-1	—
F1, F2	Reference Spot	—
F23, F24	PBS (Negative Control)	Control (-)